Although multiple advances have been made in systemic therapy for renal cell carcinoma
(RCC), metastatic RCC remains incurable. In the current review, we focus on the underlying …

The most common type of cancer originating in the kidney is renal cell carcinoma (RCC). In
both localized and advanced RCC, a number of clinical, pathologic, and molecular factors …

PURPOSE Nivolumab is standard of care for patients with metastatic clear cell renal cell
carcinoma (ccRCC) after failure of antiangiogenic therapies, but its activity on brain …

Objective To report the safety and efficacy results of patients enrolled in the Italian
Nivolumab Renal Cell Cancer Expanded Access Programme. Patients and Methods …

BACKGROUND Metastases are the hallmark of lethal cancer, though underlying
mechanisms that drive metastatic spread to specific organs remain poorly understood …

Background Nivolumab plus ipilimumab (NIVO+ IPI) has demonstrated long‐term efficacy
and safety in patients with previously untreated, advanced renal cell carcinoma (aRCC) …

Renal cell carcinoma (RCC) accounts for 3% of adult malignancies and is the eighth leading
cause of cancer in the United States. 1 Worldwide, 400,000 people were diagnosed and …

OBJECT Systemic control of metastatic renal cell carcinoma (mRCC) has substantially
improved with the development of VEGF, mTOR, and checkpoint inhibitors. The current first …

Objectives To evaluate the safety and efficacy of stereotactic radiotherapy (SRT) in patients
with metastatic renal cell carcinoma (mRCC) concurrently receiving targeted therapy (TT) or …

Brain metastases are the most common form of brain cancer. Increasing knowledge of
primary tumor biology, actionable molecular targets and continued improvements in …